Navigation Links
Can EP4 agonist alleviate gastric lesions?
Date:11/18/2009

Over 300 million patients use non-steroidal anti-inflammatory drugs (NSAIDs) in the world to treat pain, arthritis, fever and other diseases. Nearly 30% of the users suffer from gastric lesions and bleeding. To mitigate NSAIDs' adverse effects on the stomach, misoprostol, a non-selective prostaglandin E1 (PGE1) analogue, has been prescribed as the first choice for prevention of NSAID-induced injuries, but often induces severe adverse effects. There remain unmet medical needs for drugs with improved therapeutic profiles.

A research article published on November 7, 2009 in the World Journal of Gastroenterology addresses this question. A research team from United States investigated therapeutic potentials of a highly-selective EP4 agonist for treatment of a mouse gastric ulcer model in the presence or absence of indomethacin at various levels.

They found the EP4-selective agonist reduced high dose indomethacin-induced acute hemorrhagic damage and promoted mucous epithelial regeneration. Low-dose indomethacin aggravated ulcer bleeding and inflammation, and delayed the healing of the established chronic gastric ulcer. The EP4 agonist, when applied locally, not only offset indomethacin-induced gastric bleeding and inflammation, but also accelerated ulcer healing. In the absence of indomethacin, the EP4 agonist even accelerated chronic gastric ulcer healing and suppressed inflammatory cell infiltration in the granulation tissue. In vitro, the EP4 agonist protected human gastric mucous cells from indomethacin-induced apoptosis.

Their results suggest that EP4 agonists may mimic the gastric protective effects of PGE2 in the presence or absence of NSAIDs, and may show advantages over non-selective analogs such as misoprostol by minimizing adverse effects arising from activating all 4 subtype receptors of PGE2.


'/>"/>

Contact: Ye-Ru Wang
wjg@wjgnet.com
86-105-908-0039
World Journal of Gastroenterology
Source:Eurekalert

Page: 1

Related medicine news :

1. How IAP antagonist chemicals kill tumors
2. Exelixis to Receive Milestone Payment From Bristol-Myers Squibb for Achievement of Liver X Receptor Agonist Development Milestone
3. TNF-alpha antagonist stops inflammation-induced colon cancer in its tracks
4. TorreyPines Therapeutics Licenses Intellectual Property from Johns Hopkins Related to Novel Uses of Glutamate Receptor Antagonists for Prevention, Treatment of Stroke, Heart Attack
5. Galenea and Organix Announce Exclusive License Agreement for 5-HT2C Agonists for the Treatment of Obesity
6. TorreyPines NGX426, an Oral AMPA/Kainate Receptor Antagonist, Meets Primary Endpoints in Reducing Capsaicin-Induced Pain in Healthy Subjects
7. GlaxoSmithKline Statement on FDA Advisory Committee Vote on Use of Asthma Medicines Containing Long-Acting Beta-Agonists
8. Amira Announces the Successful Completion of GLP Toxicity Studies for a Novel DP2 Antagonist.
9. Shionogi Announces Positive Top-Line Efficacy Results from Year-Long Studies of Velneperit, a Novel NPY Y5 Receptor Antagonist Being Investigated for the Treatment of Obesity
10. Arena Pharmaceuticals Announces Initiation by Merck of Phase 2 Clinical Trial of Niacin Receptor Agonist
11. FDA Approves SAMSCA(TM) (tolvaptan), the First and Only Oral Vasopressin Antagonist to Treat Patients With Clinically Significant Hypervolemic and Euvolemic Hyponatremia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/23/2014)... "Many men refuse to touch the toilet in ... in urine and spit," said an inventor from Decorah, ... came up with this hygienic device." , He developed ... the toilet seat before urinating. The unit ends the ... with dirt and germs. The accessory prevents urine from ...
(Date:8/23/2014)... The report “Polycarbonate Resin Market ... to 2018” defines and segments the global polycarbonate ... global revenue and consumption. It also identifies driving ... market with analysis of trends, opportunities, burning issues, ... and revenues are forecasted on the basis of ...
(Date:8/23/2014)... York (PRWEB) August 23, 2014 ... the 2012 GranuFlo and NaturaLyte dialysis concentrate recall ... underway in U.S. District Court, District of Massachusetts, ... docket report issued by the U.S. Judicial Panel ... least 2,028 claims are pending in the proceeding. ...
(Date:8/23/2014)... 23, 2014 Peripheral intervention surgeries are ... plaques, etc, thereby addressing the root cause of peripheral ... blood to the other part of the arteries where ... These procedures require the use of a catheter, (which ... polymers), these catheters are inserted through a thin cut ...
(Date:8/23/2014)... According to the new research report, "Electronic ... - Regional Trends & Forecast to 2019," defines ... analysis and forecast of value individually. Along with ... by applications and geography are also discussed in ... and 26 figures spread through 234 pages and ...
Breaking Medicine News(10 mins):Health News:Polycarbonate Resin Market by Applications and Geography Projected to $18.3 Billion by 2018 - New Report by MarketsandMarkets 2Health News:Polycarbonate Resin Market by Applications and Geography Projected to $18.3 Billion by 2018 - New Report by MarketsandMarkets 3Health News:Polycarbonate Resin Market by Applications and Geography Projected to $18.3 Billion by 2018 - New Report by MarketsandMarkets 4Health News:GranuFlo Lawsuits Mount in Federal Litigation, as Filings Surpass 2,000, Bernstein Liebhard LLP Reports 2Health News:GranuFlo Lawsuits Mount in Federal Litigation, as Filings Surpass 2,000, Bernstein Liebhard LLP Reports 3Health News:GranuFlo Lawsuits Mount in Federal Litigation, as Filings Surpass 2,000, Bernstein Liebhard LLP Reports 4Health News:Global Peripheral Intervention Market: Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 2Health News:Global Peripheral Intervention Market: Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 3Health News:Global Peripheral Intervention Market: Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 4Health News:Electronic Adhesives Market Poised to Reach $5.5 Billion by 2019 - New Report by MarketsandMarkets 2Health News:Electronic Adhesives Market Poised to Reach $5.5 Billion by 2019 - New Report by MarketsandMarkets 3
... lutenizing hormone-releasing hormone agonist, reduces the long-term risk of ... breast cancer who did not take tamoxifen, according to ... of the Journal of the National Cancer Institute. ... hormone agonists, including goserelin, reduce the risk of disease ...
... to a cardiologist to go through a standard battery of ... coronary artery disease which is the most common cause of ... and these women are sent home with little more than ... similar symptoms and are more likely to develop future cardiac ...
... 24, 2009 Diagnosing acute stroke is a high-pressure ... all the difference. Early treatment can stop brain damage, ... increase the risk of bleeding in the brain. , ... stroke treatmenta clot-busting enzyme known as tissue plasminogen activator ...
... 23, 2009) Postpartum depression is a seriousand often ... mothers. Some of the causes might include personal history ... financial or emotional support. Left untreated, it can have ... on her child,s development. , In the ...
... Hanover Insurance Group, Inc. (NYSE: THG ... to the company,s board of directors at its ... principal of Taggart Associates in Cambridge, Mass., which ... work on corporate and non-profit boards.(Logo: http://www.newscom.com/cgi-bin/prnh/20051031/NEM023LOGO ...
... that can pose a big public health threat, researchers ... their release from Texas prisons, only 5 percent of ... treat their condition within the necessary 10 days, a ... therapy] at this time are at increased risk of ...
Cached Medicine News:Health News:Goserelin improves long-term survival in premenopausal women with early breast cancer 2Health News:Cardiologists initiate STILETTO study to investigate treatment options for women with chest pain 2Health News:Stroke treated significantly faster and just as safely by medical residents 2Health News:Stroke treated significantly faster and just as safely by medical residents 3Health News:Diabetes a risk factor for postpartum depression 2Health News:The Hanover Insurance Group Elects Harriett Tee Taggart to Board of Directors 2Health News:The Hanover Insurance Group Elects Harriett Tee Taggart to Board of Directors 3Health News:Most HIV-Infected Prisoners Go Untreated After Release 2
(Date:8/22/2014)... , Aug. 22, 2014  Medical Science Liaisons serve ... leaders in the healthcare sector. As the impact of ... is changing how Medical Science Liaisons (MSLs) interact with ... are using the tablet to not only share important ... better coordinate thought leader interactions across geographies and therapeutic ...
(Date:8/22/2014)... , August 22, 2014 ... Markets ( http://www.researchandmarkets.com/research/x34qgv/global_laboratory ) has announced the addition ... 2014-2018"  report to their offering.  ... is an essential instrument for any modern ... precise weighing of materials. It can be ...
(Date:8/22/2014)... , August 22, 2014 ... has announced the addition of the  "Global ... their offering.       (Logo: http://photos.prnewswire.com/prnh/20130307/600769) ... with a sterile environment in a healthcare ... is equipped with technically advanced equipment, which ...
Breaking Medicine Technology:iPads Enhancing Medical Science Liaison Interactions with Thought Leaders, New Study Shows 2Global Laboratory Electronic Balance Market 2014-2018: Key Vendors are A&D Company, Mettler-Toledo, Sartorius and Thermo Fisher 2Global Operating Room Equipment Market 2014-2018: Key Vendors are Getinge, STERIS, Stykron and TRUMPF Medical Systems 2
... Boston Scientific Corporation (NYSE: BSX ) announces ... be presented at Digestive Disease Week ® (DDW), ... involve the SpyGlass ® Direct Visualization System, WallFlex® ... Needle and Resolution® Clip. "The volume and ...
... Pharmaceuticals, Inc. (NYSE: WPI ) today ... an Abbreviated New Drug Application (ANDA) with the ... to market Norethindrone Acetate/Ethinyl Estradiol and Ethinyl Estradiol and ... 75 mg. Watson,s ANDA product is a generic ...
Cached Medicine Technology:Boston Scientific Endoscopy Presents Promising Clinical Data During Digestive Disease Week ® 2Boston Scientific Endoscopy Presents Promising Clinical Data During Digestive Disease Week ® 3Boston Scientific Endoscopy Presents Promising Clinical Data During Digestive Disease Week ® 4Boston Scientific Endoscopy Presents Promising Clinical Data During Digestive Disease Week ® 5Watson Confirms Lo Loestrin® Fe Patent Challenge 2Watson Confirms Lo Loestrin® Fe Patent Challenge 3
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: